Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) – Research analysts at Jefferies Financial Group issued their FY2027 earnings per share (EPS) estimates for Reneo Pharmaceuticals in a research note issued on Friday, January 27th. Jefferies Financial Group analyst E. Yang expects that the company will post earnings of $3.86 per share for the year. The consensus estimate for Reneo Pharmaceuticals' current full-year earnings is ($2.16) per share.
Get Reneo Pharmaceuticals alerts:Reneo Pharmaceuticals Stock Down 1.1 %
Shares of Reneo Pharmaceuticals stock opened at $2.68 on Monday. The firm has a market cap of $65.74 million, a price-to-earnings ratio of -1.35 and a beta of 0.50. Reneo Pharmaceuticals has a 52-week low of $1.79 and a 52-week high of $6.46. The company's 50-day simple moving average is $2.32 and its 200-day simple moving average is $2.91.
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05.Institutional Investors Weigh In On Reneo Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Reneo Pharmaceuticals by 87.0% in the 3rd quarter. Renaissance Technologies LLC now owns 43,000 shares of the company's stock valued at $144,000 after buying an additional 20,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Reneo Pharmaceuticals in the third quarter valued at $62,000. Barclays PLC boosted its position in shares of Reneo Pharmaceuticals by 33.3% during the 3rd quarter. Barclays PLC now owns 71,930 shares of the company's stock worth $241,000 after purchasing an additional 17,984 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Reneo Pharmaceuticals by 76.5% during the 2nd quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock worth $80,000 after purchasing an additional 13,000 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Reneo Pharmaceuticals in the 2nd quarter valued at about $457,000. Hedge funds and other institutional investors own 75.61% of the company's stock.
About Reneo Pharmaceuticals
(Get Rating)
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Recommended Stories
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.